09:39 AM EDT, 10/17/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said Thursday that it has nominated a new development candidate as part of its collaboration with Roche, resulting in a $15 million milestone payment from the Swiss healthcare company.

Poseida said the candidate is an allogeneic, dual CAR-T therapy that targets known antigens found in hematologic malignancies, including multiple myeloma.

The company said it and Roche had completed three programs under a collaboration agreement signed in August 2022.

Shares of Poseida Therapeutics ( PSTX ) were up more than 1% in recent trading.

Price: 2.57, Change: +0.03, Percent Change: +1.18